Skip to main content
SpringerLink
Log in

Docetaxel plus androgen deprivation withdrawal may restore sensitivity to luteinizing hormone-releasing hormone analog therapy in castration-resistant prostate cancer patients

  • Research Letter
  • Published:
Endocrine Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. W.P. Harris, E.A. Mostaghel, P.S. Nelson, B. Montgomery, Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat. Clin. Pract. Urol. 6(2), 76–85 (2009)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. T. Karantanos, C.P. Evans, B. Tombal, T.C. Thompson, R. Montironi, W.B. Isaacs, Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level. Eur. Urol. 67(3), 470–479 (2015)

    Article  CAS  PubMed  Google Scholar 

  3. H.I. Scher, K. Fizazi, F. Saad, M.E. Taplin, C.N. Sternberg, K. Miller, R. de Wit, P. Mulders, K.N. Chi, N.D. Shore, A.J. Armstrong, T.W. Flaig, A. Fléchon, P. Mainwaring, M. Fleming, J.D. Hainsworth, M. Hirmand, B. Selby, L. Seely, J.S. de Bono, AFFIRM Investigators, Increased survival with enzalutamide in prostate cancer after chemotherapy. N. Engl. J. Med. 367(13), 1187–1197 (2012)

    Article  CAS  PubMed  Google Scholar 

  4. J.S. de Bono, C.J. Logothetis, A. Molina, K. Fizazi, S. North, L. Chu, K.N. Chi, R.J. Jones, O.B. Goodman Jr, F. Saad, J.N. Staffurth, P. Mainwaring, S. Harland, T.W. Flaig, T.E. Hutson, T. Cheng, H. Patterson, J.D. Hainsworth, C.J. Ryan, C.N. Sternberg, S.L. Ellard, A. Fléchon, M. Saleh, M. Scholz, E. Efstathiou, A. Zivi, D. Bianchini, Y. Loriot, N. Chieffo, T. Kheoh, C.M. Haqq, H.I. Scher, COU-AA-301 Investigators, Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med. 364(21), 1995–2005 (2011)

    Article  PubMed  PubMed Central  Google Scholar 

  5. K. Fizazi, H.I. Scher, A. Molina, C.J. Logothetis, K.N. Chi, R.J. Jones, J.N. Staffurth, S. North, N.J. Vogelzang, F. Saad, P. Mainwaring, S. Harland, O.B. Goodman Jr, C.N. Sternberg, J.H. Li, T. Kheoh, C.M. Haqq, J.S. de Bono, COU-AA-301 Investigators, Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 13(10), 983–992 (2012)

    Article  CAS  PubMed  Google Scholar 

  6. C.J. Ryan, M.R. Smith, J.S. de Bono, A. Molina, C.J. Logothetis, P. de Souza, K. Fizazi, P. Mainwaring, J.M. Piulats, S. Ng, J. Carles, P.F. Mulders, E. Basch, E.J. Small, F. Saad, D. Schrijvers, H. Van Poppel, S.D. Mukherjee, H. Suttmann, W.R. Gerritsen, T.W. Flaig, D.J. George, E.Y. Yu, E. Efstathiou, A. Pantuck, E. Winquist, C.S. Higano, M.E. Taplin, Y. Park, T. Kheoh, T. Griffin, H.I. Scher, D.E. Rathkopf, COU-AA-302 Investigators, abiraterone in metastatic prostate cancer without previous chemotherapy. N. Engl. J. Med. 368(2), 138–148 (2013)

    Article  CAS  PubMed  Google Scholar 

  7. D.E. Rathkopf, M.R. Smith, J.S. de Bono, C.J. Logothetis, N.D. Shore, P. de Souza, K. Fizazi, P.F. Mulders, P. Mainwaring, J.D. Hainsworth, T.M. Beer, S. North, Y. Fradet, H. Van Poppel, J. Carles, T.W. Flaig, E. Efstathiou, E.Y. Yu, C.S. Higano, M.E. Taplin, T.W. Griffin, M.B. Todd, M.K. Yu, Y.C. Park, T. Kheoh, E.J. Small, H.I. Scher, A. Molina, C.J. Ryan, F. Saad, Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). Eur. Urol. 66(5), 815–825 (2014)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. I.F. Tannock, R. de Wit, W.R. Berry, J. Horti, A. Pluzanska, K.N. Chi, S. Oudard, C. Théodore, N.D. James, I. Turesson, M.A. Rosenthal, M.A. Eisenberger, TAX 327 Investigators, Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 351(15), 1502–1512 (2004)

    Article  CAS  PubMed  Google Scholar 

  9. D.R. Berthold, G.R. Pond, F. Soban, R. de Wit, M. Eisenberger, I.F. Tannock, Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J. Clin. Oncol. 26(2), 242–245 (2008)

    Article  CAS  PubMed  Google Scholar 

  10. D.P. Petrylak, C.M. Tangen, M.H. Hussain, P.N. Lara Jr, J.A. Jones, M.E. Taplin, P.A. Burch, D. Berry, C. Moinpour, M. Kohli, M.C. Benson, E.J. Small, D. Raghavan, E.D. Crawford, Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med. 351(15), 1513–1520 (2004)

    Article  CAS  PubMed  Google Scholar 

  11. J.S. de Bono, S. Oudard, M. Ozguroglu, S. Hansen, J.P. Machiels, I. Kocak, G. Gravis, I. Bodrogi, M.J. Mackenzie, L. Shen, M. Roessner, S. Gupta, A.O. Sartor, TROPIC Investigators, Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after Docetaxel treatment: a randomised open-label trial. Lancet 376(9747), 1147–1154 (2010)

    Article  CAS  PubMed  Google Scholar 

  12. M.A. Jordan, L. Wilson, Microtubules as a target for anticancer drugs. Nat. Rev. Cancer 4, 253–265 (2004)

    Article  CAS  PubMed  Google Scholar 

  13. M.S. Darshan, M.S. Loftus, M. Thadani-Mulero, B.P. Levy, D. Escuin, X.K. Zhou, A. Gjyrezi, C. Chanel-Vos, R. Shen, S.T. Tagawa, N.H. Bander, D.M. Nanus, P. Giannakakou, Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer. Cancer Res. 71(18), 6019–6029 (2011)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. E. Basch, D.A. Loblaw, T.K. Oliver, M. Carducci, R.C. Chen, J.N. Frame, K. Garrels, S. Hotte, M.W. Kattan, D. Raghavan, F. Saad, M.E. Taplin, C. Walker-Dilks, J. Williams, E. Winquist, C.L. Bennett, T. Wootton, R.B. Rumble, S.B. Dusetzina, K.S. Virgo, Systemic therapy in men with metastatic castration-resistant prostate cancer: American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline. J. Clin. Oncol. 32(30), 3436–3448 (2014)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. C.D. Taylor, P. Elson, D.L. Trump, Importance of continued testicular suppression in hormone-refractory prostate cancer. J. Clin. Oncol. 11(11), 2167–2172 (1993)

    CAS  PubMed  Google Scholar 

  16. C. Sweeney, Y.-H. Chen, M.A. Carducci, G. Liu, D. Frasier Jarrard, M.A. Eisenberger, N.-N. Wong, N.M. Hahn, M. Kohli, N.J. Vogelzang, M.M. Cooney, R. Dreicer, J. Picus, D.H. Shevrin, M. Hussain, J.A. Garcia, R.S. DiPaola, Impact on overall survival with chemohormonal therapy versus hormonal therapy for hormone-sensitive newly metastatic prostate cancer: an ECOG-led phase III randomized trial, in ASCO Annual Meeting. Abstract LBA2. Presented 1 June, 2014

  17. N.D. James, Adding chemotherapy to initial therapy improves survival in patients with advanced, hormone-naïve prostate cancer, in ASCO 2015. Abstract 5001. (STAMPEDE trial)

  18. F. Valcamonico, L. Ferrari, F. Consoli, V. Amoroso, A. Berruti, Testosterone serum levels and prostate cancer prognosis: the double face of Janus. Future Oncol. 10(7), 1113–1115 (2014)

    Article  CAS  PubMed  Google Scholar 

  19. P. Thelen, E. Heinrich, F. Bremmer, L. Trojan, A. Strauss, Testosterone boosts for treatment of castration resistant prostate cancer: an experimental implementation of intermittent androgen deprivation. Prostate 73(15), 1699–1709 (2013)

    CAS  PubMed  Google Scholar 

  20. M.T. Schweizer, E.S. Antonarakis, H. Wang, A.S. Ajiboye, A. Spitz, H. Cao, J. Luo, M.C. Haffner, S. Yegnasubramanian, M.A. Carducci, M.A. Eisenberger, J.T. Isaacs, S.R. Denmeade, Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical study. Sci. Transl. Med. 7(269), 269ra2 (2015)

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgments

The study was supported in part by donations of “gli Amici di Carlo” in memory of Carlo Ridon and “gli Amici di Andrea” in memory of Andrea Gadeschi.

Author information

Authors and Affiliations

  1. Oncology Unit, Department of Surgery, Radiology, and Public Health, University of Brescia, Spedali Civili of Brescia, Brescia, Italy

    Francesca Bedussi, Francesca Valcamonico, Laura Ferrari, Alberto Dalla Volta, Vittorio Ferrari & Alfredo Berruti

  2. Section of Pharmacology, Department of Molecular and Translational Medicine, University of Brescia, Brescia, Italy

    Francesca Bedussi, Sandra Sigala & Maurizio Memo

  3. Medical Oncology, Maggiore della Carità University Hospital, University of Eastern Piedmont, Novara, Italy

    Alessandra Mosca & Oscar Alabiso

  4. Urology, Maggiore della Carità University Hospital, University of Eastern Piedmont, Novara, Italy

    Carlo Terrone & Giansilvio Marchioro

Authors
  1. Francesca Bedussi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Francesca Valcamonico
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alessandra Mosca
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sandra Sigala
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Laura Ferrari
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Carlo Terrone
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Alberto Dalla Volta
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Giansilvio Marchioro
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Vittorio Ferrari
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Oscar Alabiso
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Maurizio Memo
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Alfredo Berruti
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Francesca Valcamonico.

Ethics declarations

Conflicts of interest

Alfredo Berruti received honoraria for speech, Advisory Board, and research grants from Astellas, Janssen, and Sanofi. Alessandra Mosca received honoraria for speech from Astellas and Sanofi.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bedussi, F., Valcamonico, F., Mosca, A. et al. Docetaxel plus androgen deprivation withdrawal may restore sensitivity to luteinizing hormone-releasing hormone analog therapy in castration-resistant prostate cancer patients. Endocrine 54, 830–833 (2016). https://doi.org/10.1007/s12020-015-0827-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12020-015-0827-z

Keywords

Search

Navigation